Please refer to the attached interview with our CEO and Co-Founder Marta Barrachina, in which she discusses the in vitro diagnostic (IVD) developed by ADmit for the prognosis of progression from mild cognitive impairment (MCI) to Alzheimer's disease dementia (ADD). Our technology is based on novel mitochondrial blood-based biomarkers and is able to determine the likelihood of ADD dementia progression even in MCI patients with a negative β-amyloid PET scan. These patients are currently not recruited for clinical trials. She outlines our commitment to gain regulatory approval to improve the accuracy of current gold standards in clinical practice. #Alzheimersdisease #AlzMoonshot #dementiawareness #EUeic #horizoneu #ADmit #nevertoodifficult #startuphealth
StartUp Health company ADmit Therapeutics has developed a prognostic blood test for Alzheimer's disease. #HealthTransformer #HealthMoonshot #AlzMoonshot #ENDALZ 📺 Watch Marta Barrachina, PhD, on StartUp Health TV ⤵️ https://lnkd.in/gCUbcJpT